Paris – Mayer Brown advised SERB Specialty Pharmaceuticals (« SERB »), independent pharmaceutical company in connection with the acquisition of the Veriton Pharma Limited Group, a British pharmaceutical group, from its founder-manager and other members of the management team.
Mayer Brown advised SERB on the structuring of the acquisition with a team composed of Laurent Borey, Olivier Parawan (partners) and Sarah Rahmoun (associate) in Paris and Matthew Mortimer (partner) and Matthew O'Brien (associate) in London.
